Treatment of cutaneous leishmaniasis in travelers 2009

Journal of Travel Medicine

Volumn 16, Issue 2, 2009, Pages 123-131

  Blum, Johannes A ^a   Hatz, Christoph F ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIMONY DERIVATIVE; AZITHROMYCIN; FLUCONAZOLE; IMIQUIMOD; IMMUNOMODULATING AGENT; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PENTAMIDINE ISETHIONATE; PENTAMIDINE MESYLATE; PENTOXIFYLLINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ABSCESS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; CARDIOTOXICITY; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIARRHEA; EMPORIATRICS; EXFOLIATIVE DERMATITIS; FEVER; GASTROINTESTINAL DISEASE; GLOMERULONEPHRITIS; HEADACHE; HEART ARRHYTHMIA; HEPATITIS; HERPES ZOSTER; HUMAN; HYPERAMYLASEMIA; HYPERPYREXIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTENSION; INJECTION SITE PAIN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY TUBULE DISORDER; LEUKOPENIA; LIVER TOXICITY; MALAISE; MOTION SICKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEURITIS; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SKIN ALLERGY; SKIN LEISHMANIASIS; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TROPICS; UNSPECIFIED SIDE EFFECT; UREMIA;

ANIMALS; ANTIFUNGAL AGENTS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; DRUG THERAPY, COMBINATION; HUMANS; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; TRAVEL;

EID: 63049091280     PISSN: 11951982     EISSN: 17088305     Source Type: Journal    
DOI: 10.1111/j.1708-8305.2008.00286.x     Document Type: Review

References (100)

1. Caumes E, Carriere J, Guermonprez G, et al. Dermatoses associated with travel to tropical countries: a prospective study of the diagnosis and management of 269 patients presenting to a tropical disease unit. Clin Infect Dis 1995 20 : 542 548.
2. Blum J, Junghanss T, Hatz C. Erroneous tracks in the diagnosis of cutaneous and mucocutaneous leishmaniasis. Schweiz Rundsch Med Prax 1994 83 : 1025 1029.
3. Lawn SD, Whetham J, Chiodini PL, et al. New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. QJM 2004 97 : 781 788.
4. Blum J, Desjeux P, Schwartz E, et al. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 2004 53 : 158 166.
5. Schwartz E, Hatz C, Blum J. New world cutaneous leishmaniasis in travellers. Lancet Infect Dis 2006 6 : 342 349.
6. Minodier P, Parola P. Cutaneous leishmaniasis treatment. Travel Med Infect Dis 2007 5 : 150 158.
7. Bailey MS, Lockwood DN. Cutaneous leishmaniasis. Clin Dermatol 2007 25 : 203 211.
8. Scarisbrick JJ, Chiodini PL, Watson J, et al. Clinical features and diagnosis of 42 travellers with cutaneous leishmaniasis. Travel Med Infect Dis 2006 4 : 14 21.
9. Magill AJ. Cutaneous leishmaniasis in the returning traveler. Infect Dis Clin North Am 2005 19 : 241 266.
10. Soto J, Arana A, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004 38 : 1266 1272.
11. Soto J, Rea J, Balderrama M, et al. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 2008 78 : 210 211.
12. Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin Infect Dis 2008 46 : 223 231.
13. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992 46 : 296 306.
14. Antezana G, Zeballos R, Mendoza C, et al. Electrocardiographic alterations during treatment of mucocutaneous leishmaniasis with meglumine antimoniate and allopurinol. Trans R Soc Trop Med Hyg 1992 86 : 31 33.
15. Ribeiro AL, Drummond JB, Volpini AC, et al. Electrocardiographic changes during low-dose, short-term therapy of cutaneous leishmaniasis with the pentavalent antimonial meglumine. Braz J Med Biol Res 1999 32 : 297 301.
16. Lawn SD, Armstrong M, Chilton D, et al. Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers. Trans R Soc Trop Med Hyg 2006 100 : 264 269.
17. Hepburn NC, Siddique I, Howie AF, et al. Hepatotoxicity of sodium stibogluconate in leishmaniasis. Lancet 1993 342 : 238 239.
18. Hepburn NC. Thrombocytopenia complicating sodium stibogluconate therapy for cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1993 87 : 691.
19. Aronson NE, Wortmann GW, Johnson SC, et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. Clin Infect Dis 1998 27 : 1457 1464.
20. Gasser RA Jr., Magill AJ, Oster CN, et al. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994 18 : 83 90.
21. Rodrigues ML, Costa RS, Souza CS, et al. Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis. Rev Inst Med Trop Sao Paulo 1999 41 : 33 37.
22. Brummitt CF, Porter JA, Herwaldt BL. Reversible peripheral neuropathy associated with sodium stibogluconate therapy for American cutaneous leishmaniasis. Clin Infect Dis 1996 22 : 878 879.
23. Wortmann GW, Aronson NE, Byrd JC, et al. Herpes zoster and lymphopenia associated with sodium stibogluconate therapy for cutaneous leishmaniasis. Clin Infect Dis 1998 27 : 509 512.
24. Hellier I, Dereure O, Tournillac I, et al. Treatment of Old World cutaneous leishmaniasis by pentamidine isethionate. An open study of 11 patients. Dermatology 2000 200 : 120 123.
25. Lightburn E, Morand JJ, Meynard JB, et al. Management of American cutaneous leishmaniasis. Outcome apropos of 326 cases treated with high-dose pentamidine isethionate. Med Trop (Mars) 2003 63 : 35 44.
26. Delobel P, Pradinaud R. Rhabdomyolysis associated with pentamidine isethionate therapy for American cutaneous leishmaniasis. J Antimicrob Chemother 2003 51 : 1319 1320.
27. Nacher M, Carme B, Sainte MD, et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol 2001 95 : 331 336.
28. Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 1993 16 : 417 425.
29. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg 2006 100 (Suppl 1 S26 S33.
30. Soto J, Berman J. Treatment of new world cutaneous leishmaniasis with miltefosine. Trans R Soc Trop Med Hyg 2006 100 (Suppl 1 S34 S40.
31. Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med 1990 89 : 147 155.
32. Arana BA, Mendoza CE, Rizzo NR, et al. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 2001 65 : 466 470.
33. Weinrauch L, Cawich F, Craig P, et al. Topical treatment of new world cutaneous leishmaniasis in Belize: a clinical study. J Am Acad Dermatol 1993 29 : 443 446.
34. Navin TR, Arana BA, Arana FE, et al. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992 165 : 528 534.
35. Ballou WR, McClain JB, Gordon DM, et al. Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis. Lancet 1987 2 : 13 16.
36. Wortmann G, Miller RS, Oster C, et al. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin Infect Dis 2002 35 : 261 267.
37. Martinez S, Gonzalez M, Vernaza ME. Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Clin Infect Dis 1997 24 : 165 169.
38. Martinez S, Marr JJ. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 1992 326 : 741 744.
39. Pradinaud R. Le traitement de la leishmaniose tégumentaire par la pentamidine en Guyane française. Med Trop (Mars) 1994 54 : 418 422.
40. Lai AF, Vrede MA, Soetosenojo RM, et al. Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. Int J Dermatol 2002 41 : 796 800.
41. Roussel M, Nacher M, Fremont G, et al. Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana. Ann Trop Med Parasitol 2006 100 : 307 314.
42. Arevalo J, Ramirez L, Adaui V, et al. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis 2007 195 : 1846 1851.
43. Herwaldt BL. Leishmaniasis. Lancet 1999 354 : 1191 1199.
44. Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007 44 : 350 356.
45. el-On J, Halevy S, Grunwald MH, et al. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol 1992 27 : 227 231.
46. el-On J, Livshin R, Paz ZE, et al. Topical treatment of cutaneous leishmaniasis. J Invest Dermatol 1985 291 : 1280 1281.
47. Asilian A, Jalayer T, Nilforooshzadeh M, et al. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull World Health Organ 2003 81 : 353 359.
48. Junaid AJ. Treatment of cutaneous leishmaniasis with infrared heat. Int J Dermatol 1986 25 : 470 472.
49. al Majali O, Routh HB, Abuloham O, et al. A 2-year study of liquid nitrogen therapy in cutaneous leishmaniasis. Int J Dermatol 1997 36 : 460 462.
50. Bassiouny A, El Meshad M, Talaat M, et al. Cryosurgery in cutaneous leishmaniasis. Br J Dermatol 1982 107 : 467 474.
51. Leibovici V, Aram H. Cryotherapy in acute cutaneous leishmaniasis. Int J Dermatol 1986 25 : 473 475.
52. Alkhawajah AM, Larbi E, al Gindan Y, et al. Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration. Ann Trop Med Parasitol 1997 91 : 899 905.
53. Tallab TM, Bahamdam KA, Mirdad S, et al. Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate. Int J Dermatol 1996 35 : 594 597.
54. Faris RM, Jarallah JS, Khoja TA, et al. Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony. Int J Dermatol 1993 32 : 610 612.
55. Alrajhi AA, Ibrahim EA, De Vol EB, et al. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002 346 : 891 895.
56. Mohebali M, Fotouhi A, Hooshmand B, et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 2007 103 : 33 40.
57. Rahman SB, ul Bari A, Mumtaz N. Miltefosine in cutaneous leishmaniasis. J Coll Physicians Surg Pak 2007 17 : 132 135.
58. Uzun S, Durdu M, Culha G, et al. Clinical features, epidemiology, and efficacy and safety of intralesional antimony treatment of cutaneous leishmaniasis: recent experience in Turkey. J Parasitol 2004 90 : 853 859.
59. Lessa HA, Machado P, Lima F, et al. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 2001 65 : 87 89.
60. Amato VS, Tuon FF, Siqueira AM, et al. Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg 2007 77 : 266 274.
61. Amato VS, Tuon FF, Bacha HA, et al. Mucosal leishmaniasis current scenario and prospects for treatment. Acta Trop 2008 105 : 1 9.
62. Seaton RA, Morrison J, Man I, et al. Out-patient parenteral antimicrobial therapy - a viable option for the management of cutaneous leishmaniasis. Q J Med 1999 92 : 659 667.
63. Matoussi N, Ameur HB, Amor SB, et al. Cardiotoxicity of n-methyl-glucamine antimoniate (Glucantime). A case report. Med Mal Infect 2007 37 (Suppl 3 S257 S259.
64. Romero GA, Guerra MV, Paes MG, et al. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 2001 65 : 456 465.
65. Hadighi R, Boucher P, Khamesipour A, et al. Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Parasitol Res 2007 101 : 1319 1322.
66. Soto J, Toledo J, Gutierrez P, et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis 2001 33 : E57 E61.
67. Morizot G, Delgiudice P, Caumes E, et al. Healing of Old World cutaneous leishmaniasis in travelers treated with fluconazole: drug effect or spontaneous evolution? Am J Trop Med Hyg 2007 76 : 48 52.
68. Nassiri-Kashani M, Firooz A, Khamesipour A, et al. A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 2005 19 : 80 83.
69. Weinrauch L, Livshin R, el-On J. Ketoconazole in cutaneous leishmaniasis. Br J Dermatol 1987 117 : 666 668.
70. Weinrauch L, Livshin R, Even-Paz Z, et al. Efficacy of ketoconazole in cutaneous leishmaniasis. Arch Dermatol Res 1983 275 : 353 354.
71. Teixeira AC, Paes MG, Guerra JO, et al. Low efficacy of azithromycin to treat cutaneous leishmaniasis in Manaus, AM, Brazil. Rev Inst Med Trop Sao Paulo 2007 49 : 235 238.
72. Layegh P, Yazdanpanah MJ, Vosugh EM, et al. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 2007 77 : 99 101.
73. Daoud S, Boushi L. Azithromycin, ineffective in the treatment of old-world cutaneous leishmaniasis. Int J Dermatol 2006 45 : 1126 1128.
74. Minodier P, Zambelli L, Mary C, et al. Cutaneous leishmaniasis treated with azithromycin in a child. Pediatr Infect Dis J 2008 27 : 80 81.
75. Silva-Vergara ML, Silva LA, Maneira FR, et al. Azithromycin in the treatment of mucosal leishmaniasis. Rev Inst Med Trop Sao Paulo 2004 46 : 175 177.
76. Arevalo I, Ward B, Miller R, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001 33 : 1847 1851.
77. Arevalo I, Tulliano G, Quispe A, et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis 2007 44 : 1549 1554.
78. Miranda-Verastegui C, Llanos-Cuentas A, Arevalo I, et al. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis 2005 40 : 1395 1403.
79. Firooz A, Khamesipour A, Ghoorchi MH, et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol 2006 142 : 1575 1579.
80. Almeida R, D'Oliveira A Jr., Machado P, et al. Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous leishmaniasis. J Infect Dis 1999 180 : 1735 1737.
81. Santos JB, de Jesus AR, Machado PR, et al. Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study. J Infect Dis 2004 190 : 1793 1796.
82. Almeida RP, Brito J, Machado PL, et al. Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials. Am J Trop Med Hyg 2005 73 : 79 81.
83. Machado PR, Lessa H, Lessa M, et al. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 2007 44 : 788 793.
84. Bafica A, Oliveira F, Freitas LA, et al. American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline. Int J Dermatol 2003 42 : 203 207.
85. Sadeghian G, Nilforoushzadeh MA. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol 2006 45 : 819 821.
86. Badaro R, Lobo I, Munos A, et al. Immunotherapy for drug-refractory mucosal leishmaniasis. J Infect Dis 2006 194 : 1151 1159.
87. Sadeghian G, Nilfroushzadeh MA, Iraji F. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate. Clin Exp Dermatol 2007 32 : 371 374.
88. Panagiotopoulos A, Stavropoulos PG, Hasapi V, et al. Treatment of cutaneous leishmaniasis with cryosurgery. Int J Dermatol 2005 44 : 749 752.
89. Mosleh IM, Geith E, Natsheh L, et al. Efficacy of a weekly cryotherapy regimen to treat Leishmania major cutaneous leishmaniasis. J Am Acad Dermatol 2008 58 : 617 624.
90. Asilian A, Sharif A, Faghihi G, et al. Evaluation of CO laser efficacy in the treatment of cutaneous leishmaniasis. Int J Dermatol 2004 43 : 736 738.
91. Asilian A, Sadeghinia A, Faghihi G, et al. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Ann Trop Med Parasitol 2003 97 : 493 498.
92. Asilian A, Sadeghinia A, Faghihi G, et al. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 2004 43 : 281 283.
93. Harms G, Schonian G, Feldmeier H. Leishmaniasis in Germany. Emerg Infect Dis 2003 9 : 872 875.
94. Weitzel T, Muhlberger N, Jelinek T, et al. Imported leishmaniasis in Germany 2001-2004: data of the SIMPID surveillance network. Eur J Clin Microbiol Infect Dis 2005 24 : 471 476.
95. Antinori S, Gianelli E, Calattini S, et al. Cutaneous leishmaniasis: an increasing threat for travellers. Clin Microbiol Infect 2005 11 : 343 346.
96. El Hajj L, Thellier M, Carriere J, et al. Localized cutaneous leishmaniasis imported into Paris: a review of 39 cases. Int J Dermatol 2004 43 : 120 125.
97. Zeegelaar JE, Steketee WH, van Thiel PP, et al. Changing pattern of imported cutaneous leishmaniasis in the Netherlands. Clin Exp Dermatol 2005 30 : 1 5.
98. Bryceson AD, Murphy A, Moody AH. Treatment of 'Old World' cutaneous leishmaniasis with aminosidine ointment: results of an open study in London. Trans R Soc Trop Med Hyg 1994 88 : 226 228.
99. Garnier T, Croft SL. Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs 2002 3 : 538 544.
100. Morgan DJ, Guimaraes LH, Machado PR, et al. Cutaneous leishmaniasis during pregnancy: exuberant lesions and potential fetal complications. Clin Infect Dis 2007 45 : 478 482.